SARS-CoV-2 Spike S1 Antagonist Antibodies for COVID-19, Primed for Clinical Development
Quickly tap into a large market opportunity in antiviral therapeutic and diagnostic applications.
Vaccines and neutralizing therapeutic antibodies against SARS-CoV-2 have been pivotal in the treatment of the virus. However, several SARS-CoV-2 variants have emerged and the probability that this virus remains a seasonal cause of morbidity and mortality is high. Therefore, the pursuit of new antibodies for therapeutic and diagnostic applications, at all stages of disease progression, is an important priority.